Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of...
Reexamination Certificate
1993-11-19
2002-01-08
Guzo, David (Department: 1636)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
C435S363000, C435S366000, C435S320100, C536S023100, C536S023200, C536S023500, C536S023700, C536S024100
Reexamination Certificate
active
06337209
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to molecular chimaeras in infective virions: methods of their construction; pharmaceutical formulations containing them; their use in therapy, particularly virus-directed enzyme prodrug therapy, particularly in the treatment of cancers, and more particularly in the treatment of hepatocellular and colorectal carcinomas; and the use of agents which can be catalysed by a heterologous enzyme to cytotoxic or cytostatic metabolites, such as purine arabinosides and substituted pyrimidines and cytosines in virus-directed enzyme prodrug therapy in a host(e.g., mammal or human).
BACKGROUND OF THE INVENTION
Cancer of all forms is one of the major causes of morbidity throughout the world. Research in cancer chemotherapy has produced a variety of antitumour agents with differing degrees of efficacy. Standard clinically used agents include adriamycin, actinomycin D, methotrexate, 5-fluorouracil, cisplatin, vincristine and vinblastine. However, these presently available antitumour agents are known to have various disadvantages such as toxicity to healthy cells and resistance of certain tumour types. Other forms of therapy, such as surgery, are known. However it is appreciated by those skilled in the art that novel approaches and entities for cancer therapy are still needed.
Hepatocellular carcinoma (HCC) is one of the major malignant diseases in the world today; the greatest incidence being in Japan, China, other parts of Asia, and sub-Saharan Africa. Recent evidence suggests that the incidence of hepatocellular carcinoma in Europe and North America is increasing. The disease is estimated to be responsible for or involved in up to approximately 1,250,000 deaths a year, making it one of the world's major malignant diseases.
The prognosis of HCC is always poor, with the worldwide frequency rate almost equalling the mortality rate. After diagnosis, the median survival time is less than four months. Long-term survival, defined as survival longer than one year after diagnosis, is seen only occasionally. Most HCC patients succumb to either the complications of liver failure with or without massive bleeding, or to the general effects of a large tumour burden, with cachexia, malnutrition, infection, and sepsis. Though distant metastases occur (up to 90% of patients have metastatic tumour at time of death), regional disease most often limits survival. Consequently, therapies directed toward control of hepatic tumours are appropriate, although it will be appreciated that treatment of the metastatic disease is also of great importance(Kew M. C. Postgrad. Med. J. 59 (Suppl. 4) 78-87 (1983) and Berk P. (Ed) Semin. Liver Dis. 4, No.2, Thieme-Stratton Inc. N.Y. (1984)).
Current therapies available to the clinician are basically ineffective as a curative treatment for this disease (Nerenstone S. R., lhde D. C., Friedman M. A. Cancer Treat. Rev. 15, 1-31 (1988)). To date, surgery continues to be the only potentially curative treatment. However, at the time of diagnosis, the overwhelming majority of patients are not able to undergo radical surgery. In certain studies (Nerenstone et al supra) less than 3% of patients were considered capable of undergoing surgery and of the small percentage that do undergo surgery, approximately 50% suffer from postoperative morbidity (Nerenstone et al supra).
Colorectal carcinoma(CRC) is the second most frequent cancer and the second leading cause of cancer-associated deaths in the United States and Western Europe(Silverberg, E. CA 33, 9-25(1983); Silverberg, E. CA 36, 9-25(1986); Farley, P. C., and McFaden, K. H. Postgrad. Med. 84, 175-183)(1988). The overall five-year survival rate for patients has not meaningfully improved in the last three decades. Prognosis for the CRC cancer patient is associated with the depth of tumor penetration into the bowel wall, the presense of regional lymph node involvement and, most importantly, the presense of distant metastases. The liver is the most common site for distant metastasis and, in approximately 30% of patients, the sole initial site of tumor recurrence after successful resection of the primary colon cancer(Daly, J. M., and Kemeny, N. Import. Adv. Oncol. 251-286(1986) ). Hepatic metastases are the most common cause of death in the CRC cancer patient(Swinton, N. W., et al., Dis. Colon Rectum 7, 273-277(1964) ).
The treatment of choice for the majority of patients with hepatic CRC metastasis is systemic or regional chemotherapy using 5-fluorouracil(5-FU) alone or in combination with other agents such as leviamasole(for a review see Daly, J. M., and Kemeny, N. (1986) Import. Adv. Oncol.251-286). However, despite extensive effort, there is still no satisfactory treatment for hepatic CRC metastasis.
Systemic single- and combination-agent chemotherapy and radiation are relatively ineffective emphasizing the need for new approaches and therapies for the treatment of these diseases.
REFERENCES:
patent: 4521406 (1985-06-01), Kawamura et al.
patent: 4975278 (1990-12-01), Senter et al.
patent: 5358866 (1994-10-01), Mullen et al.
patent: 5624830 (1997-04-01), Mullen et al.
patent: 5691177 (1997-11-01), Guber et al.
patent: 5925345 (1999-07-01), Blaese et al.
patent: 0 181 150 (1986-05-01), None
patent: 0243204 (1987-10-01), None
patent: 0 272 065 (1988-06-01), None
patent: 0 273 127 (1988-07-01), None
patent: 0 293 193 (1988-11-01), None
patent: 0 293 193 (1988-11-01), None
patent: 0 294 114 (1988-12-01), None
patent: 0 334 301 (1989-09-01), None
patent: 0 415 731 (1991-03-01), None
patent: WO 89/07136 (1989-08-01), None
patent: WO 90/07936 (1990-07-01), None
patent: WO 91/02805 (1991-03-01), None
patent: 92/04901 (1992-04-01), None
patent: 92/10564 (1992-06-01), None
patent: 93/01281 (1993-01-01), None
patent: 93/21959 (1993-11-01), None
Felgner et al. “Lipofection:A highly efficient, lipid-mediated DNA-transfection procedure”, PNAS, vol. 84, pp. 7413-7417, Nov. 1987.*
Moolton, Medical Hypotheses, vol. 24, pp. 43-51, 1987.
Nishiyama et al., “Antineoplastic Effects in Rats of 5-Fluorocytosine in Combination with Cytosine Deaminase Capsules”, Cancer Res., vol. 45, pp 1753-1761, Apr. 1985.*
Borrelli et al., “Tapestry of an Inducible Toxic Phenotype in Animal Cells”, PNAS, vol. 85, pp. 7572-7576, Oct. 1988.*
Maxwell et al, “Targeted Cell Suicide by Toxin Gene Expression”, Gene Transfer and Gene Therapy, pp. 189-204 (1989).*
Borrelli et al, “Inducible Ablation of a Specific Cell Type by the Herpes Thymidine Kinase Gene Expression”, Gene Transfer and Gene Therapy, pp. 163-177 (1989).*
Berkner, Kathleen L., “Development of Adenovirus Vectors for the Expression of Heterologous Genes”, Biotechniques 6:616-629 (1988).*
Stratford-Perricaudet et al, “Evaluation of the Transfer and Expression in Mice of an Enzyme-Encoding Gene Using a Human Adenovirus Vector”, Human Gene Therapy 1:241-256 (1990).*
Ballay et al, “In vitro and in vivo synthesis of the hepatitis B virus surface antigen and of the receptor for polymerized human serum albumin from recombinant adenoviruses”, The EMBO Journal 4(13B):3861-3865 (1985).*
Andersen et al., “Pyrimidine, Purine and Nitrogen Control of Cytosine Deaminase Synthesis inEscherichia coliK12. Involvement of the gln LG and pur R Genes in the Regulation of cod A Expression”, Arch. Microbiol., vol. 152, pp 115-118, 1989.
Thompson et al., PNAS, vol. 84, pp. 2965-2969, May 1987.*
J. Brink et al.,Canadian J. Biochem.,43:1-15 (No. 1) (1965).
T. Krenitsky et al.,J. Biol. Chem.,251:4055-4061 (Nov. 13) (1976).
T. Haskell,Ann. N.Y. Acad. Sci.,284:81-90 (1977).
E. De Clercq et al.,J. Med. Chem.,26:661-666 (No. 5) (1983).
C.A. Richards et al.,Cancer Research,50:1521-1527 (1990).
J.R. De Wet et al.,Molecular and Cellular Biology,7:725-737 (1987).
E. Reist et al.,J. Org. Chem.,27:3274-3279 (1962).
J. Goodchild et al.,J. Med. Chem.,26:1252-1257 (No. 9) (1983).
H. Machida et al.,Antimicrobial Agents Chemother.,17:1030-1031 (No. 6) (1980).
Y. Cheng et al.,Biochem. Pharmacol.,32:726-729 (No. 4) (1983).
J. Locker et al.,J. DNA Sequencing and Mapping,1:3-11 (1990).
C. Richards et al.,J.
Huber Brian
Richards Cynthia A.
Bennett, Esq. Virginia C.
Glaxo Wellcome Inc.
Guzo David
LandOfFree
Molecular constructs containing a carcinoembryonic antigen... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Molecular constructs containing a carcinoembryonic antigen..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Molecular constructs containing a carcinoembryonic antigen... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2870592